Although PD1, VEGF and HER2 inhibitors have been proven to improve the survival rate of advanced EA and some of them have been approved as first-line and second-line treatments, the survival rate of EA is still very low (Barsouk et al. 2019). This evidence concerns the gene VEGFA and Esophageal atresia.